Bioprogress doesn't think its name reflected its forward progress, having trashed many investors hopes by buying companies to boost turnover.
So this is a name change that will herald a . . . ah, much the same....IMHO.

I'm not sure Meldex is sufficiently neutral a name, nor is it very dynamic - it seems to demonstrate that old matra...."If you can't think of anything good to do (to improve a business), change the Name and Logo..."

Let's hope it works, for those still holding in hope. I sold out about 6 months ago at a small profit as they'd dipped to silly prices. There was no good news then and I've not heard anything sufficiently exciting since.
Bit of a middling, meddling name IMHO.
(Bioprogress was perfectly OK as far as it went), unfortunately this site's software doesn't allow the sp-graph to include the earlier fluctuations.

-Good luck.-
EDIT:
BPRG over the last 5-years fluctuated from about 40p to 160 early-on then with a couple of peaks about 1 it settled towards an averaged pposition of 70p, but recent expectations of building a World-class product-enhansing ( or Patent Busting depending who is speaking) has left the sp below 50p.
I have said they need to determine if they are on Patent-enhancing ( for big Pharma), or Patent-busting....by going Generic with knobs-on. I cannot see they can be both, since Big Pharma already knows the best tricks (and has a mightly efficient sales-force), BPRG should be looking at Generics with a Plus....the trouble is that puts into conflict with really dodgy operators as well as many large-volume operators, who can undercut them on price and volume delivery.

Wishbone, my understanding is that BM retains that holding from early days....so he paid a lot less, I presume. Therefore it's worth his while Holding and waiting - it can't get below his cost yet-awhile.
Suppose he paid 10p - after this time he'll expect to more than double, won't he?
That being the case any talk of ( earlier holders) being very keen on the Stock is irrelevant, since they cannot sell-out without damaging their return. IF the sp goes to 1 (and stays there, based on ROCE, dividend etc), then they might sell into a strong Market. So far, that's not been possible.

Look at recent moves - a bit of excitement and "new product" and what happens? - the shares move down almost as soon as the Ann is filed. This company does not appear to be able to build its sp...and I suspect this is because it's all very fragile.

Grief, this is a loser! Let's review:
Poor performance (look at sp!)
Director issues
Change of Name
Growth by acquisition
Disasterous AGM
Two Directors walk
Two new Directors sell significant shares to provide working-cash
-yet we are told by some that this is a profitable business, with cash income and potential profits from their wonderful technology that Big Pharma will pay $$$'s for...er, if you believe that - - -

Hangon, would you like to be raising cash for a business in the present environment?

trouble is cashflow can easily dry up if debtors turn into bad debts.